Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
Also Known As:
Age Related Osteoporosis; Age-Related Bone Loss; Age-Related Bone Losses; Age-Related Osteoporoses; Bone Loss, Age Related; Bone Losses, Age-Related; Osteoporoses; Osteoporoses, Age-Related; Osteoporoses, Senile; Osteoporosis, Age Related; Osteoporosis, Post Traumatic; Post-Traumatic Osteoporoses; Post-Traumatic Osteoporosis; Senile Osteoporoses; Age-Related Osteoporosis; Bone Loss, Age-Related; Osteoporosis, Age-Related; Osteoporosis, Post-Traumatic; Osteoporosis, Senile; Senile Osteoporosis
Networked: 18925 relevant articles (1331 outcomes, 2850 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Bone Resorption
2. Neoplasms (Cancer)
3. Breast Neoplasms (Breast Cancer)
4. Metabolic Bone Diseases (Osteopenia)
5. Cardiovascular Diseases (Cardiovascular Disease)


1. Reginster, Jean-Yves: 69 articles (02/2015 - 03/2002)
2. Boonen, Steven: 57 articles (09/2015 - 01/2002)
3. Miller, Paul D: 53 articles (06/2015 - 05/2002)
4. Iwamoto, Jun: 51 articles (10/2015 - 01/2002)
5. Adachi, Jonathan D: 49 articles (10/2015 - 01/2002)
6. Lewiecki, E Michael: 49 articles (08/2015 - 11/2002)
7. Shiraki, Masataka: 47 articles (12/2015 - 03/2002)
8. Sugimoto, Toshitsugu: 44 articles (09/2015 - 04/2002)
9. Rizzoli, R: 43 articles (12/2015 - 01/2000)
10. Bilezikian, John P: 43 articles (01/2014 - 03/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Osteoporosis:
1. DiphosphonatesIBA
2. Alendronate (Alendronate Sodium)FDA LinkGeneric
3. Estrogens (Estrogen)FDA Link
4. CalciumIBA
5. Vitamin DFDA LinkGeneric
6. risedronic acid (risedronate)FDA LinkGeneric
7. Raloxifene (Evista)FDA Link
8. Teriparatide (Parathar)FDA Link
9. strontium ranelate (protelos)IBA
12/01/2008 - "These data demonstrate a significant vertebral antifracture efficacy of strontium ranelate in young postmenopausal women aged 50-65 years with severe osteoporosis and confirm the efficacy of this antiosteoporotic treatment to prevent vertebral fractures, whatever the age of the patient."
01/01/2005 - "The antifracture efficacy of strontium ranelate, 2 g/day orally, an agent that appears to have dissociation effects on resorption and formation, has been assessed in two large, randomized, double-blind, placebo-controlled clinical studies: the Spinal Osteoporosis Therapeutic Intervention (SOTI) trial and the TReatment Of Peripheral Osteoporosis Study (TROPOS), including more than 6,700 postmenopausal women. "
06/01/2010 - "The purpose of this review is to analyze whether the fracture-reducing efficacy of strontium ranelate in patients with osteoporosis can be achieved independently of sex, etiology of osteoporosis, and the major diagnostically relevant risk factors."
02/01/2009 - "The Spinal Osteoporosis Therapeutic Intervention trial established that strontium ranelate decreased the incidence of vertebral fractures, but had little effect on the incidence of non-vertebral fractures. "
12/01/2008 - "The Spinal Osteoporosis Therapeutic Intervention (SOTI) was an international, double blind, placebo controlled trial, supporting the efficacy of strontium ranelate 2 g/day in reducing the risk of vertebral fractures in postmenopausal women with osteoporosis and a prevalent vertebral fracture. "
10. HormonesIBA

Therapies and Procedures

1. Hormone Replacement Therapy (Therapy, Hormone Replacement)
2. Ovariectomy (Oophorectomy)
3. Drug Therapy (Chemotherapy)
4. Estrogen Replacement Therapy
5. Vertebroplasty